No Breast Cancer association with Vitamin D (none had enough) – Jan 2023

Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts

Eur J Epidemiol . 2023 Jan;38(1):11-29. doi: 10.1007/s10654-022-00921-1
Publisher wants $50 for the PDF PDF can be viewed on free DeepDyve trial

After callibration there were no Vitamin D levels > 30 ng

Yet figure 2 shows many studies with > 30 ng

Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls. Median age (interdecile range) was 57 (42-68) years at blood collection and 63 (49-75) years at breast cancer diagnosis. Prediagnostic circulating 25(OH)D was either newly measured using a widely accepted immunoassay and laboratory or, if previously measured by the cohort, calibrated to this assay to permit using a common metric. Study-specific relative risks (RRs) for season-standardized 25(OH)D concentrations were estimated by conditional logistic regression and combined by random-effects models. Circulating 25(OH)D increased from a median of 22.6 nmol/L in consortium-wide decile 1 to 93.2 nmol/L in decile 10. Breast cancer risk in each decile was not statistically significantly different from risk in decile 5 in models adjusted for breast cancer risk factors, and no trend was apparent (P-trend = 0.64).
Compared to women with sufficient 25(OH)D based on Institute of Medicine guidelines (50- < 62.5 nmol/L), RRs were not statistically significantly different at either low concentrations (< 20 nmol/L, 3% of controls) or high concentrations (100- < 125 nmol/L, 3% of controls; ≥ 125 nmol/L, 0.7% of controls). RR per 25 nmol/L increase in 25(OH)D was 0.99 [95% confidence intervaI (CI) 0.95-1.03]. Associations remained null across subgroups, including those defined by body mass index, physical activity, latitude, and season of blood collection.
Although none of the associations by tumor characteristics reached statistical significance, suggestive inverse associations were seen for distant and triple negative tumors. Circulating 25(OH)D, comparably measured in 17 international cohorts and season-standardized, was not related to subsequent incidence of invasive breast cancer over a broad range in vitamin D status.

17 Trials
  1. Beta-Carotene and Retinol Efficacy Trial (CARET)
  2. CLUE II: Campaign Against Cancer and Heart Disease (CLUE II)
  3. Cancer Prevention Study-II (CPS-II)
  4. Multiethnic Cohort Study (MEC)
  5. Nurses’ Health Study (NHS)
  6. Nurses’ Health Study II (NHSII)
  7. New York University Women’s Health Study (NYU WHS)
  8. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
  9. Women’s Health Initiative (WHI)
  10. Women’s Health Study (WHS)
  11. Breakthrough Generations Study (BGS)
  12. Etude Epidémiologique auprès de femmes de l'Education Nationale (E3N)
  13. European Investigation into Cancer and Nutrition (EPIC)
  14. JANUS Serum Bank (JANUS)
  15. Malmd Diet and Cancer Study
  16. Northern Sweden Health and Disease Study (NSHDS)
  17. Hormones and Diet in the Etiology of Breast Cancer (ORDET)

VitaminDWiki – Overview Breast Cancer and Vitamin D contains

Previous Charts of Breast Cancer and Vitamin D ( >40 ng is good)

A poor Vitamin D Receptor may result in higher BC risk than poor Vitamin D

  • Vitamin D Receptor has
  • Has the risk of Breast Cancer due to poor Vitamin D Receptor increased in past decades?
  • Image
22 VDR studies of Breast Cancer

This list is automatically updated

(Rejected) Letter to Editor by Dr. Grant

The recent article by Visvanathan et al. conducted a pooled analysis of 17 prospective cohort studies of breast cancer incidence with respect to baseline serum 25-hydroxyvitamin D [25(OH)D] concentration in an effort to determine whether vitamin D reduces risk of breast cancer [1]. Even though the range of 25(OH)D concentration extended from <20 nmol/L to >125 nmol/L, no significant correlations between 25(OH)D concentration and incidence of breast cancer were found. As the authors noted in the introduction, there is compelling evidence that vitamin D can inhibit cancer initiation and progression in experimental models. Thus, two questions arise: 1 – has vitamin D status been found to reduce risk of breast cancer incidence using other epidemiological approaches?; and, 2 – what might be the problem with prospective observational studies for breast and other types of cancer?
Regarding the first question, both case-control (CC) studies with serum 25(OH)D concentrations measured near time of breast cancer diagnosis and geographical ecological studies have found strong support for vitamin D and solar UVB dose, an index of vitamin D production, in reducing breast cancer incidence and/or mortality rates [2]. CC studies are usually overlooked regarding the role of vitamin D in health outcomes for two reasons: 1 – that the disease state might affect serum 25(OH)D concentrations (reverse causality); and 2 – that the choice of controls might introduce bias. As for the disease state affecting 25(OH)D concentrations, as was discussed in 2, it is mainly found with acute inflammatory illnesses that reduce serum 25(OH)D concentrations near the time of disease onset.
A good example is COVID-19, for which the body’s immune response often includes rapidly raising proinflammatory cytokine concentrations, thereby raising inflammatory biomarkers such as C-reactive protein, and reducing 25(OH)D concentrations. The physiological indication is a fever. However, the increase in C-reactive
protein associated with cancer incidence is very small, and cancer patients do not have fevers. As for matching
controls, approaches such as propensity score matching are now being applied, which helps ensure that cases and
controls are well matched. Also, since the findings for breast cancer risk reduction with respect to 25(OH)D
concentrations from CC studies are very similar, it does not appear that bias is an important concern.
What are the problems with prospective observational studies of cancer with respect to serum 25(OH)D
concentrations? As shown in 2011, the longer the follow-up time, the smaller the observed difference in cancer
incidence rates between high and low baseline 25(OH)D concentrations 3. In Figure 1 of [3], for four studies with
>4 years of follow up, no significant reductions of breast cancer with respect to 25(OH)D concentration were found.
(This is essentially the same as for the 17 studies included in [1] as in that article’s Figure 3.) However, for CC
studies and one prospective study with a 3-year follow up, the mean relative risk (RR) for breast cancer incidence
with respect to 25(OH)D concentrations was near 0.6 and was significant for all studies. For colorectal cancer
(CRC), RR was significantly below one out to 14 years of follow up. As mentioned in [3], there is evidence that
breast cancer tumors can develop very rapidly to a size that is easily detected. That is consistent with the fact that
breast cancer screening is recommended every one-to-two years, while CRC screening is recommended every ten
It is noted that a meta-analysis of 17 cohort studies regarding CRC incidence from this consortium found a
significantly reduced odds ratio (OR) for CRC incidence with respect to serum 25(OH)D concentration for women,
but not for men 4. As shown in Figure 1 in [2] for a similar analysis of OR vs. follow-up time for CRC showed
that when the OR are plotted vs. median follow-up time to diagnosis, the OR for zero years of follow up is 0.77 for
males and 0.74 for females, in stark contrast to their finding that results were not significant for men. The reason
why no significant reduction in CRC risk was found for men is that the slope of the OR for men was 0.031/year
while that for women was 0.0081/year. Why the slopes differ is not known.

Additional support for the fact that breast cancer tumors can grow rapidly to detectable size is given in an analysis of breast cancer seasonality [5]. They included observational studies from 64 global regions over time spans from 2 to 53 years. The primary finding was that in the northern hemisphere, breast cancer incidence is more frequently detected from September through November and again from February or March through May or June, with the
minimum of detection in July and August and a weaker minimum from December to February until April. They
hypothesized that solar UVB production of vitamin D explained the summer minimum, and that increased melatonin
due to weak solar radiation levels in winter explained the winter minimum. They cited a number of articles
regarding the role of melatonin in reducing risk of breast cancer. Figure 5 in [5] shows a model pattern for relative
breast tumor volume vs. time oscillating from lower in summer and winter, higher in spring and fall, superimposed
on a continuously rising trend.

Conclusion: The role of vitamin D in reducing risk of breast and other cancers should be evaluated using findings
from mechanism studies, geographical ecological studies, observational studies using either short follow-up times
after blood draw for serum 25(OH)D concentration measurements or correction for long follow-up times, and
properly designed randomized controlled trials, i.e., based on serum 25(OH)D concentrations, enrolling participants
with low 25(OH)D concentrations, and giving large vitamin D doses [2]. In addition, the assumptions regarding the
reliability of various approaches should be carefully studied.

Funding: The author declares that no funds, grants, or other support were received during the preparation of this manuscript.
Competing Interests: I receive funding from Bio-Tech Pharmacal, Inc. (Fayetteville, AR, USA).

  • 1. Visvanathan K, Mondul AM, Zeleniuch-Jacquotte A, et al. Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts. Eur J Epidemiol. 2023. doi:10.1007/s10654-022-00921-1
  • 2. Muñoz A, Grant WB. Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms. Nutrients. 2022;14(7):1448. doi:10.3390/nu14071448
  • 3. Grant WB. Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: Implications for meta-analyses and setting vitamin D guidelines. Dermatoendocrinol. 2011;3(3):199-204. doi:10.4161/derm.3.3.15364
  • 4. McCullough ML, Zoltick ES, Weinstein SJ, et al. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. J Natl Cancer Inst. 2019;111(2):158-69. doi:10.1093/jnci/djy087
  • 5. Oh EY, Ansell C, Nawaz H, Yang CH, Wood PA, Hrushesky WJ. Global breast cancer seasonality. Breast Cancer Res Treat. 2010;123(1):233-43. doi:10.1007/s10549-009-0676-7

 Download the lettter to editor

Study References
  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. . - DOI
  2. World Health Organization, International Agency for Research on Cancer. Global Cancer Observatory. 2021 cited 2021.
  3. Dietary reference intakes for calcium and vitamin D. Washington, D.C.: The National Academies Press; 2011.
  4. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342–57. . - DOI
  5. Welsh J. Function of the vitamin D endocrine system in mammary gland and breast cancer. Mol Cell Endocrinol. 2017;453:88–95. . - DOI
  6. Kim Y, Franke AA, Shvetsov YB, et al. Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case-control study in the Multiethnic Cohort Study. BMC Cancer. 2014;14:29. . - DOI
  7. Engel P, Fagherazzi G, Boutten A, et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomark Prev. 2010;19(9):2341–50. . - DOI
  8. Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomark Prev. 2005;14(8):1991–7. . - DOI
  9. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer. 2010;127(9):2159–68. . - DOI
  10. Neuhouser ML, Manson JE, Millen A, et al. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol. 2012;175(7):673–84. . - DOI
  11. Scarmo S, Afanasyeva Y, Lenner P, et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res. 2013;15(1):R15. . - DOI
  12. Amir E, Cecchini RS, Ganz PA, et al. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat. 2012;133(3):1077–88. . - DOI
  13. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res. 2011;13(3):R50. . - DOI
  14. Kuhn T, Kaaks R, Becker S, et al. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int J Cancer. 2013;133(7):1689–700. . - DOI
  15. Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev. 2008;17(4):889–94. - DOI
  16. McCullough ML, Stevens VL, Patel R, et al. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009;11(4). .
  17. Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM, Vitamin DSP. Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl. 2012;243:32–40. . - DOI
  18. Carter GD, Berry J, Durazo-Arvizu R, et al. Hydroxyvitamin D assays: an historical perspective from DEQAS. J Steroid Biochem Mol Biol. 2018;177:30–5. . - DOI
  19. Estebanez N, Gomez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and risk of breast cancer: a meta-analysis. Sci Rep. 2018;8(1):9039. . - DOI
  20. Hossain S, Beydoun MA, Beydoun HA, Chen X, Zonderman AB, Wood RJ. Vitamin D and breast cancer: a systematic review and meta-analysis of observational studies. Clin Nutr ESPEN. 2019;30:170–84. . - DOI
  21. Song D, Deng Y, Liu K, et al. Vitamin D intake, blood vitamin D levels, and the risk of breast cancer: a dose-response meta-analysis of observational studies. Aging (Albany NY). 2019;11(24):12708–32. . - DOI
  22. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100(22):1581–91. - DOI
  23. Cauley JA, Chlebowski RT, Wactawski-Wende J, et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women’s Health Initiative. J Womens Health (Larchmt). 2013;22(11):915–29. . - DOI
  24. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. Am J Clin Nutr. 2011;94(4):1144–9. . - DOI
  25. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8. . - DOI
  26. World Cancer Research Fund, American Institute for Cancer Research. Continuous Update Project Expert Report 2018 Internet. Diet, nutrition, physical activity, and breast cancer. 2018 cited 2021. Available from
  27. Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N, Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomark Prev. 2013;22(7):1319–24. . - DOI
  28. Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res. 1994;54(7 Suppl):2038s-s2043.
  29. Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012;130(4):921–9. . - DOI
  30. Swerdlow AJ, Jones ME, Schoemaker MJ, et al. The breakthrough generations study: design of a long-term UK cohort study to investigate breast cancer aetiology. Br J Cancer. 2011;105(7):911–7. . - DOI
  31. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304. . - DOI
  32. Langseth H, Gislefoss RE, Martinsen JI, Dillner J, Ursin G. Cohort profile: the janus serum bank cohort in Norway. Int J Epidemiol. 2017;46(2):403–4. . - DOI
  33. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr. 2008;88(2):507S-S510. . - DOI
  34. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42(15):1549–56. . - DOI
  35. Rousseeuw PJ, Leroy AM. Robust regression and outlier detection. New York: Wiley; 1987. - DOI
  36. Sloan A, Song Y, Gail MH, et al. Design and analysis considerations for combining data from multiple biomarker studies. Stat Med. 2019;38(8):1303–20. . - DOI
  37. Gail MH, Wu J, Wang M, et al. Calibration and seasonal adjustment for matched case-control studies of vitamin D and cancer. Stat Med. 2016;35(13):2133–48. . - DOI
  38. Bliss CI. Periodic regression in biology and climatology. New Haven, Connecticut Agricultural Experiment Station; 1958.
  39. Prentice RL, Breslow NE. Retrospective studies and failure time models. Biometrika. 1978;65:153–8. - DOI
  40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. . - DOI
  41. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–29. - DOI
  42. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551–61. . - DOI
  43. Smith PL. Splines as a useful and convenient statistical tool. Am Stat. 1979;33:57–62.
  44. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514–27. . - DOI
  45. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–23. . - DOI
  46. Budhathoki S, Hidaka A, Yamaji T, et al. Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan Public Health Center-based Prospective Study cohort. BMJ. 2018;360: k671. . - DOI
  47. Deschasaux M, Souberbielle JC, Latino-Martel P, et al. Weight status and alcohol intake modify the association between vitamin D and breast cancer risk. J Nutr. 2016;146(3):576–85. . - DOI
  48. Eliassen AH, Warner ET, Rosner B, et al. Plasma 25-Hydroxyvitamin D and risk of breast cancer in women followed over 20 years. Cancer Res. 2016;76(18):5423–30. . - DOI
  49. Ordonez-Mena JM, Schottker B, Haug U, et al. Serum 25-hydroxyvitamin D and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomark Prev. 2013;22(5):905–16. . - DOI
  50. Skaaby T, Husemoen LL, Thuesen BH, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomark Prev. 2014;23(7):1220–9. . - DOI
  51. Heath AK, Hodge AM, Ebeling PR, et al. Circulating 25-Hydroxyvitamin D concentration and risk of breast, prostate, and colorectal cancers: the Melbourne Collaborative Cohort Study. Cancer Epidemiol Biomark Prev. 2019;28(5):900–8. . - DOI
  52. Acikgoz A, Cimrin D, Ergor G. Effect of serum 25-hydroxyvitamin D level on lung, breast, colorectal and prostate cancers: a nested case-control study. East Mediterr Health J. 2020;26(7):794–802. . - DOI
  53. O’Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum vitamin D and risk of breast cancer within five years. Environ Health Perspect. 2017;125(7): 077004. . - DOI
  54. McDonnell SL, Baggerly CA, French CB, et al. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations >/=60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. PLoS ONE. 2018;13(6): e0199265. . - DOI
  55. Zhu K, Knuiman M, Divitini M, et al. Lower serum 25-hydroxyvitamin D is associated with colorectal and breast cancer, but not overall cancer risk: a 20-year cohort study. Nutr Res. 2019;67:100–7. . - DOI
  56. Ordonez-Mena JM, Schottker B, Fedirko V, et al. Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. Eur J Epidemiol. 2016;31(3):311–23. . - DOI
  57. Peila R, Rohan TE. Association of Prediagnostic Serum Levels of Vitamin D with Risk of Ductal Carcinoma In Situ of the Breast in the UK Biobank Cohort Study. Cancer Epidemiol Biomark Prev. 2022;31(7):1499–502. . - DOI
  58. Zhou L, Chen B, Sheng L, Turner A. The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis. Breast Cancer Res Treat. 2020;182(1):1–8. . - DOI
  59. Manson JE, Bassuk SS, Buring JE, Group VR. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol. 2020;198:105522. . - DOI
  60. Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019;30(5):733–43. . - DOI
  61. Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. . - DOI
  62. Chandler PD, Chen WY, Ajala ON, et al. Effect of vitamin D3 supplements on development of advanced cancer: a secondary analysis of the VITAL randomized clinical trial. JAMA Netw Open. 2020;3(11): e2025850. . - DOI
  63. McCullough ML, Zoltick ES, Weinstein SJ, et al. Circulating vitamin D and colorectal cancer risk: an international pooling project of 17 cohorts. J Natl Cancer Inst. 2019;111(2):158–69. . - DOI
  64. McCullough ML, Weinstein SJ, Freedman DM, et al. Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172(1):21–35.
  65. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomark Prev. 2010;19(4):927–31. . - DOI
  66. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol. 2010;171(8):903–8. . - DOI

There have been 1966 visits to this page

1749 visitors, last modified 05 Feb, 2023,
Printer Friendly Follow this page for updates